RedHill Biopharma (RDHL) Competitors

Cognition Therapeutics (NASDAQ:CGTX) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Does the MarketBeat Community prefer CGTX or RDHL?

RedHill Biopharma received 401 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 74.29% of users gave Cognition Therapeutics an outperform vote while only 65.69% of users gave RedHill Biopharma an outperform vote.

Company	Underperform	Outperform
Cognition Therapeutics	Outperform Votes 26 74.29%	Underperform Votes 9 25.71%
RedHill Biopharma	Outperform Votes 427 65.69%	Underperform Votes 223 34.31%

Do analysts rate CGTX or RDHL?

Cognition Therapeutics currently has a consensus price target of $5.63, suggesting a potential upside of 1,785.69%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than RedHill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
RedHill Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has stronger valuation and earnings, CGTX or RDHL?

RedHill Biopharma has higher revenue and earnings than Cognition Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$25.79M	-$0.74	-0.40
RedHill Biopharma	$8.04M	0.50	$23.92M	N/A	N/A

Is CGTX or RDHL more profitable?

RedHill Biopharma's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-150.93%	-100.82%
RedHill Biopharma	N/A	N/A	N/A

Do insiders and institutionals hold more shares of CGTX or RDHL?

43.3% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by company insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more volatility and risk, CGTX or RDHL?

Cognition Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 4.23, suggesting that its share price is 323% more volatile than the S&P 500.

Does the media favor CGTX or RDHL?

In the previous week, Cognition Therapeutics had 1 more articles in the media than RedHill Biopharma. MarketBeat recorded 2 mentions for Cognition Therapeutics and 1 mentions for RedHill Biopharma. RedHill Biopharma's average media sentiment score of 1.89 beat Cognition Therapeutics' score of 1.44 indicating that RedHill Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
RedHill Biopharma	Very Positive

Summary

Cognition Therapeutics beats RedHill Biopharma on 8 of the 15 factors compared between the two stocks.